Summit Therapeutics plc (SMMT) Analysts See $-0.76 EPS on June, 13

May 17, 2018 - By Megan Stone

Summit Therapeutics plc (NASDAQ:SMMT) Corporate Logo

Earnings report for Summit Therapeutics plc (NASDAQ:SMMT) is anticipated on June, 13., as reported by RTT. Analysts have anticipation on stock’s earnings per share of $-0.76. That’s down 52.00 % from last year’s $-0.5 earnings per share. -33.91 % EPS growth is what analysts predict. $-1.15 earnings per share was published for previous quarter. Ticker’s shares touched $13.95 during the last trading session after 1.82% change.Summit Therapeutics plc is uptrending after having risen 4.52% since May 17, 2017. SMMT has 79,366 volume or 105.88% up from normal. SMMT underperformed by 7.03% the S&P 500.

Summit Therapeutics plc (NASDAQ:SMMT) Ratings Coverage

In total 8 analysts cover Summit Therapeutics plc – American Depositary Shares (NASDAQ:SMMT). “Buy” rating has 8, “Sell” are 0, while 0 are “Hold”. (NASDAQ:SMMT) has 100% bullish analysts. 10 are the (NASDAQ:SMMT)’s ratings reports on May 17, 2018 according to StockzIntelligence Inc. On Tuesday, March 6 Canaccord Genuity maintained the shares of SMMT in report with “Buy” rating. On Friday, December 1 the stock has “Buy” rating by H.C. Wainwright. On Friday, April 13 the rating was maintained by SunTrust with “Buy”. On Friday, January 26 the stock has “Outperform” rating by Oppenheimer. On Wednesday, April 11 the stock of Summit Therapeutics plc (NASDAQ:SMMT) has “Buy” rating given by Canaccord Genuity.

Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat genetic and infectious diseases in the United Kingdom and North America.The firm is worth $218.72 million. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy and the infectious disease Clostridium difficile infection (CDI).Last it reported negative earnings. The companyÂ’s lead DMD product candidate is ezutromid, an orally administered small molecule, which is in Phase II clinical trial in patients with DMD; and lead CDI product candidate is ridinilazole, an orally administered small molecule antibiotic that has completed Phase II clinical trials for the treatment of CDI disease.

For more Summit Therapeutics plc (NASDAQ:SMMT) news posted briefly go to: Globenewswire.com, Globenewswire.com, Nasdaq.com, Globenewswire.com or Streetinsider.com. The titles are as follows: “Summit Therapeutics plc : Notice of AGM” posted on May 03, 2018, “Summit Therapeutics plc : Total voting rights” on May 01, 2018, “Summit Highlights Discovery of a Series of New Mechanism Antibiotics for the Treatment of Gonorrhoea in Late …” with a publish date: April 23, 2018, “Award of Share Options and Restricted Stock Units” and the last “Summit Therapeutics (SMMT) Announces New 24-Week Analyses from PhaseOut DMD” with publication date: April 20, 2018.

Summit Therapeutics plc (NASDAQ:SMMT) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: